/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BELITE BIO INC - ADR

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$151.21 0.0063(0.63%) BLTE at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 151
Highest Today 155
Today’s Open 151
Prev. Close 150.84
52 Week High 160.55
52 Week Low 49.00
Day’s Range: Low 151 High 155
52-Week Range: Low 49.00 High 160.55
1 day return -
1 Week return +11.62
1 month return +37.4
3 month return +129.4
6 month return +156.23
1 year return +129.67
3 year return +373.14
5 year return -
10 year return -

Institutional Holdings

State Street Corp 0.06

Geode Capital Management, LLC 0.04

SPDR® Portfolio Emerging Markets ETF 0.03

Marshall Wace Asset Management Ltd 0.03

Citadel Advisors Llc 0.02

SPDR® S&P Emerging Markets Small Cap ETF 0.02

JPMorgan Chase & Co 0.02

Fidelity Nasdaq Composite Index 0.02

Fidelity Nasdaq Composite ETF 0.02

Renaissance Technologies Corp 0.01

BNP Paribas Arbitrage, SA 0.01

Cubist Systematic Strategies, LLC 0.01

UBS Group AG 0.01

Virtus LifeSci Biotech Clinical Trls ETF 0.01

ActivePassive International Equity ETF 0.01

GAMMA Investing LLC 0.00

Virtus Investment Advisors (VIA) 0.00

SPDR® S&P China ETF 0.00

Point72 Asset Management, L.P. 0.00

Bank of America Corp 0.00

CIBC US Broad Market Index 0.00

JHVIT Total Stock Market Index I 0.00

Morgan Stanley - Brokerage Accounts 0.00

Caitong International Asset Management Co., Limited. 0.00

SBI Securities Co Ltd 0.00

Advisor Group Holdings, Inc. 0.00

Ameriprise Financial Inc 0.00

Goldman Sachs Group Inc 0.00

QRG QP: Emerging Markets ADR Beta 0.00

QRG QP: Factor EM ADR VMQ 0.00

Tower Research Capital LLC 0.00

Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 5315.89 M

PB Ratio 19.6044

PE Ratio 0.0

Enterprise Value 5228.60 M

Total Assets 152.13 M

Volume 189535

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-31426000 -31.4M, FY22:-12475000 -12.5M, FY21:-9792000 -9.8M, FY20:-5753000 -5.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-21690000 -21.7M, Q2/2025:-16320000 -16.3M, Q1/2025:-14277000 -14.3M, Q3/2024:-8679000 -8.7M, Q2/2024:-9494000 -9.5M

Fund house & investment objective

Company Information Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Organisation Biotechnology

Employees 25

Industry Biotechnology

CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow